The psychedelic drug ibogaine, derived from an African plant, has been used to treat addictions. At least some participants of this forum have tried micro doses of ibogaine in an attempt to treat Parkinson’s disease.
healthunlocked.com/parkinso...
Earlier this year, the following article was published:
Marton, Soledad, et al. "Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits." Frontiers in pharmacology 10 (2019): 193.
frontiersin.org/articles/10...
Researchers administered a single dose of ibogaine at fairly high levels to rats by injection (20 mg/kg or 40 mg/kg.). They looked at the effect on various areas in the brain, including the substantia nigra. They examined the expression of GDNF and BDNF messenger RNA. They also looked at the levels of the actual proteins in the brain areas.
The gene expression of BDNF was increased at both dosages, whereas the gene expression of GDNF was increased at the higher dosage.
The actual protein BDNF was not found at a higher level. The actual protein GDNF was substantially elevated in some rats in the substantia nigra (resulting in a significantly higher average amount).
Benfotiamine (Fat Soluble Form Of Vitamin B1) and AD
Can we give CuATSM a try without waiting for the Australian trial completion (5 years from now)
